Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review

Neutrophil–lymphocyte ratio (NLR) is a biomarker of the systemic inflammatory response. The objective of this systematic scoping review was to examine the literature on NLR and inflammatory bowel disease (IBD). PubMed, Embase, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, Cochrane Specialized Regist...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 10; no. 18; p. 4219
Main Authors Langley, Blake O., Guedry, Sara E., Goldenberg, Joshua Z., Hanes, Douglas A., Beardsley, Jennifer A., Ryan, Jennifer Joan
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 17.09.2021
MDPI
Subjects
Biomarkers
Blood
Citation management software
Clinical medicine
Coronaviruses
Costs
COVID-19
Endoscopy
Expenditures
Feces
Health care access
Human subjects
Inflammatory bowel disease
Librarians
Lymphocytes
Neutrophils
Patients
R&D
Research & development
Review
Severe acute respiratory syndrome coronavirus 2
Online AccessGet full text

Cover

More Information
Summary:Neutrophil–lymphocyte ratio (NLR) is a biomarker of the systemic inflammatory response. The objective of this systematic scoping review was to examine the literature on NLR and inflammatory bowel disease (IBD). PubMed, Embase, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, Cochrane Specialized Register, DOAJ, PDQT, Biosis Citation Index, Scopus, and Web of Science were systematically searched. A total of 2621 citations yielding 62 primary studies were synthesized under four categories: distinguishing patients with IBD from controls, disease activity differentiation, clinical outcome prediction, and association of NLR with other IBD biomarkers. Thirty-eight studies employed receiver operating characteristic (ROC) curve analysis to generate optimal NLR cutpoints for applications including disease activity differentiation and prediction of response to treatment. Among the most promising findings, NLR may have utility for clinical and endoscopic disease activity differentiation and prediction of loss of response to infliximab (IFX). Overall findings suggest NLR may be a promising IBD biomarker. Assessment of NLR is non-invasive, low cost, and widely accessible given NLR is easily calculated from blood count data routinely and serially monitored in patients with IBD. Further research is justified to elucidate how evaluation of NLR in research and clinical practice would directly impact the quality and cost of care for patients living with IBD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10184219